FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

Media Formats

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Comments

Overview
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.
Released July 28, 2017

Recommended

Details

Comments

Overview
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.
Released July 28, 2017